Business Wire

First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome

Share

On Friday, 12th April, 2024, Professor Julia Scarisbrick of University of Birmingham presented interim findings from the Kyowa Kirin, Inc. (Kyowa Kirin, TSA: 4151)-sponsored study, “Real-World Observational Study of Mogamulizumab in Adult Patients with Mycosis Fungoides and Sézary Syndrome (PROSPER)”, a prospective observational study evaluating the real-world impact of mogamulizumab on disease symptoms and health-related quality of life (HRQoL) in patients with these subtypes of cutaneous T-cell lymphoma (CTCL).

CTCL is a rare form of non-Hodgkin lymphoma that most prominently affects the skin, presenting as patches, plaques, tumours, or reddening of the entire skin, and may be associated with severe itching. In a proportion of cases, the disease may spread to the lymph nodes, blood, and/or other organs.

In the current interim analysis, symptom scores (mean) were reported for 20 adult patients with relapsed or refractory disease (8 MF; 12 SS) over their first 16 weeks of mogamulizumab treatment. Prior to treatment initiation, patients reported their symptom burden using a 1 – 10 numeric scale. At baseline, skin itch scored highest (6.6) followed by skin redness (6.2), flaking skin (5.9) and skin pain (4.0). Additionally, over half of patients reported having sleep problems either “frequently” or “every night” while 47% reported difficulties regulating body temperature “frequently” or “always”.

Improvement in all symptoms was reported within 4 weeks of treatment initiation and by week 16, symptom severity had decreased considerably with the greatest improvement seen in skin redness (-2.9) closely followed by skin itch (-2.7), flaking skin (-2.5) and skin pain (-2.2). Of note, the proportion of patients reporting sleep problems or difficulties regulating body temperature either “frequently” or “always” decreased to less than 20%.

“We know that CTCL patients not only suffer from the stress of a cancer diagnosis, but that these stresses are compounded by painful, red, scaly, and itchy lesions, tumours, and varying levels of discomfort,” says study principal investigator, Prof. Julia Scarisbrick of the University of Birmingham. “The PROSPER study is helping us understand these burdens better and the impact mogamulizumab may have on patients’ symptoms and quality of life.”

To view the full press release, click here.

KKI/INT/MOG/1081
Date of Preparation: April 2024

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Contacts for Kyowa Kirin Co., Ltd.:
Media
Name: Jonathon Sheppard
Email: Jonathon.sheppard@kyowakirin.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SLB OneSubsea Awarded Contract for Phase 3, Stage 2 of Equinor’s North Sea Troll Project24.5.2024 14:00:00 CEST | Press release

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240524523658/en/ SLB OneSubsea is leveraging North Sea compliant, configurable equipment for Equinor’s North Sea Troll project. (Photo: Business Wire) SLB (NYSE: SLB) has announced the award of a sizeable contract by Equinor to its OneSubsea™ joint venture. The award leverages an existing long-term contract for the execution of the second stage of Phase 3 for Equinor’s Troll project in the North Sea, offshore Norway. To accelerate field delivery of the subsea tieback to existing infrastructure, SLB OneSubsea will leverage configurable solutions compliant with NCS2017+ for standardized subsea production systems for application in the Norwegian Continental Shelf (NCS). The objective for Troll Phase 3, Stage 2 is to accelerate production from the reservoir equivalent to about 55 billion standard cubic meters of gas. “We deeply appreciate our long-standing relations

Alipay Supports Xi’an to Build “International Consumer Friendly Tourist Destination”24.5.2024 13:15:00 CEST | Press release

Alipay, the leading digital payment and lifestyle service platform, today announced that it is working with Xi’an, the world-renowned ancient capital city located in Shaanxi province famous for the Terracotta Warriors, to launch the “International Consumer Friendly Tourist Destination” initiative. With the resurgence of inbound tourism to China, the initiative aims to enhance the travel and shopping experiences of international visitors to Xi’an and boost the city’s tourism industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240524320945/en/ Launch ceremony of “International Consumer Friendly Tourist Destination” Xi’an (Photo: Business Wire) Alipay – with the support and guidance of local authorities – is working with its partners in Xi’an, including tourist attractions, hotels, restaurants, and public transit agencies, to upgrade their payment and digital services for international travelers. International visitors can

Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO ®24.5.2024 12:05:00 CEST | Press release

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts highlighting the breadth and depth of the company’s screening and diagnostic portfolio at the American Society of Clinical Oncology® (ASCO®) Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, Ill. Presentations will include new data confirming both the predictive and prognostic value of the Oncotype DX Breast Recurrence Score® test in racially and ethnically diverse patients. Exact Sciences will also present data on its approach to multi-cancer early detection (MCED) across multiple tumor types, plus additional real-world evidence showing optimized screening adherence strategies for the Cologuard® test as well as high adherence rates for repeat screenings. “Exact Sciences’ growing evidence shows that earlier and more personalized treatment interventions lead to greater success for people living with cancer. Therefore, effective cancer screening and di

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia ® and Xgeva ® (denosumab) Biosimilar Candidate HLX1424.5.2024 12:00:00 CEST | Press release

Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the marketing authorization applications (MAAs) for HLX14, an investigational Prolia® and Xgeva® (denosumab) biosimilar. Denosumab has been approved in various countries and regions under different trade names for a range of different indications such as for the treatment of osteoporosis in postmenopausal women at high risk for fracture, among others. In 2019, it was estimated that 32 million Europeans ages 50 or above had osteoporosis, 25.5 million of which were women.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240524114174/en/ The submissions were based on a randomized, double-blind, international multicenter, parallel-controlled phase 3 clinical study that aimed to compare the efficacy, safety, tolerability, and immunogenicity of HLX14 with EU-sourced reference denosumab (Prolia) in

SERES Unveils the MF Platform to Transform Luxury Vehicles With Intelligent Technology24.5.2024 11:00:00 CEST | Press release

Chinese new energy vehicle company SERES Auto has launched its MF platform for intelligent luxury vehicles. The new platform is designed to integrate technologies across safety, power, chassis, and software systems, enabling SERES to respond to dynamic market demands and consumer expectations. "SERES Group's development is rooted in a 'user-centric' approach, focusing on software-defined vehicles," said Zhang Xinghai, Founder and Chairman of SERES Auto. "We will continue to advance our leadership in technology, and further collaborate with global business partners to provide SERES users all over the world with an ultimate experience throughout the entire lifecycle of vehicle use." SERES MF platform’s key features span four key areas, notably safety, power, versatility, and intelligence. The MF platform's safety features cover over 150 scenarios with more than 200 safety features and incorporate 40 safety technologies. Diverse power options are also a part of the MF platform, which is c

HiddenA line styled icon from Orion Icon Library.Eye